Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Enovix Corporation Q1 2026 Earnings Call - Silicon Anode Batteries Break Commercial Traction in Smart Eyewear and Drones
Enovix is successfully transitioning from a technology validation phase to early-stage commercialization. Q1 2026 revenue of $7.6 million beat the high end of guidance, driven by defense and drone shi...
- Q1 2026 revenue was $7.6 million, beating the high end of guidance and up 49% year-over-year, driven by defense and drone shipments.
- Enovix commenced commercial production of its AI-1 battery for a lead smart eyewear customer, with initial shipments underway and a ramp expected in H2 2026.
- The company secured new design wins in the drone, defense, and industrial markets, with the global pipeline for products manufactured in Korea now exceeding $130 million.
- +9 more takeaways
AmpliTech Group Q1 2026 Earnings Call - Margins Surge on ORAN Radio Momentum, Revenue Back-Loaded
AmpliTech Group delivered a sharp Q1 2026 beat on both top and bottom lines, driven by a 48.6% year-over-year revenue jump to $5.35 million and a dramatic gross margin expansion from 33% to 48%. The c...
- Revenue surged 48.6% YoY to $5.35 million in Q1 2026, up from $3.6 million in Q1 2025, driven by strong demand for 5G ORAN radio solutions.
- Gross margin expanded significantly from 33% to 48%, with gross profit more than doubling to $2.57 million, reflecting improved operational leverage and reduced initial deployment costs.
- Net loss narrowed 17.3% YoY to $1.52 million, as the company continues to scale operations and manage expenses.
- +7 more takeaways
Ascend Wellness Holdings Q1 2026 Earnings Call - Margin Expansion and Regulatory Catalyst
Ascend Wellness Holdings reported a resilient Q1 2026, with revenue of $116.9 million slightly down 3% sequentially due to post-holiday seasonality and severe winter weather. Despite lower top-line gr...
- Revenue of $116.9 million decreased 3% sequentially, reflecting post-holiday softness and weather-related disruptions, though results beat management guidance.
- Adjusted EBITDA of $26.3 million surprised to the upside, driven by a 70 basis point expansion in gross profit margins to 46.1% as vertical sales mix improved.
- The U.S. Department of Justice rescheduled medical cannabis to Schedule III, a historic regulatory shift that management views as a catalyst for improved capital access and tax clarity.
- +7 more takeaways
Allogene Therapeutics Q1 2026 Earnings Call - ALPHA3 CAR-T Data Redefines First-Line Lymphoma Treatment Paradigm
Allogene Therapeutics is shifting the CAR-T narrative from platform ambition to clinical proof. The company’s lead program, cema-cel, delivered a 58.3% MRD clearance rate in the ALPHA3 trial, a 41.6 p...
- cema-cel achieved a 58.3% MRD clearance rate in the ALPHA3 trial, compared to 16.7% in the observation arm, representing a 41.6 percentage point absolute difference.
- The interim futility analysis of ALPHA3 showed no cytokine release syndrome, ICANS, or treatment-related hospitalizations, enabling outpatient management for most patients.
- Median ctDNA levels decreased by nearly 98% in the cema-cel arm by day 45, while the observation arm saw a 26% increase.
- +9 more takeaways
Planet 13 Holdings Q1 2026 Earnings Call - Federal Rescheduling and Hemp Crackdown Drive Strategic Pivot
Planet 13 Holdings reported a transitional first quarter for 2026, with total revenue declining to $21.1 million from $25.2 million in Q4. However, this drop was largely driven by the one-time exit fr...
- Total revenue fell to $21.1 million in Q1 2026 from $25.2 million in Q4, a decline primarily attributed to the exit from California wholesale and the absence of a one-time Florida loyalty accrual benefit.
- Underlying retail revenue was approximately flat sequentially when adjusting for non-recurring items, with April performance tracking in line with internal Q2 plans.
- SuperStore revenue, including the DAZED! experience, generated $9.3 million, showing marginal growth despite a broader Las Vegas tourism market that remains roughly 7% below 2024 levels.
- +7 more takeaways
Health In Tech Q1 2026 Earnings Call - Aggressive Distribution Push and New Metrics Signal Scaling Ambitions
Health In Tech reported Q1 2026 revenue of $8.8 million, a modest 9% year-over-year increase, while deliberately burning cash to fund a major expansion in broker distribution and technology developmen...
- Q1 2026 revenue reached $8.8 million, reflecting a 9% year-over-year increase, while management reaffirmed full-year 2026 revenue guidance of $45 million to $50 million, representing 35%-50% growth.
- Health In Tech introduced two new key performance indicators: contracted revenue of $22.9 million for the remainder of 2026 and platform placed plan value (PPPV) of $82 million in Q1, replacing the discontinued 'enrolled employees' metric to better reflect long-term revenue visibility and ecosystem value.
- The company raised approximately $7 million through a PIPE financing in March 2026, which is being deployed to expand its broker distribution network, add carrier partners, and enhance its AI-driven technology architecture.
- +7 more takeaways
AEye Inc Q1 2026 Earnings Call - Revenue Ramps 60% as Defense and ITS Deployments Accelerate
AEye reported a 60% year-over-year revenue increase to $101,000, driven by a broadening commercial pipeline and early-stage deployments across defense, intelligent transportation, and autonomous truck...
- Revenue grew 60% year-over-year to $101,000, marking the strongest quarterly performance to date and signaling early-stage commercial traction.
- Active customer count increased from 16 to 21, with issued quotes and active engagements rising nearly 40% quarter-over-quarter.
- Defense and intelligent transportation systems (ITS) are emerging as primary growth drivers, with active OPTIS deployments in California and expanding UAV/UGV evaluations.
- +7 more takeaways
Dyadic International Q1 2026 Earnings Call - Commercial Shift Gains Traction as Revenue Jumps 182%
Dyadic International is shedding its label as a pure-play technology developer and is now executing a commercial strategy across life sciences, food, and nutrition markets. First-quarter revenue surge...
- Revenue surged 182% year-over-year to $1.1 million in Q1 2026, driven by a $220,000 increase in research and development revenue from grant-funded programs and partnership activity.
- Internal R&D expenses declined modestly to $476,000, reflecting a strategic reduction in active internal initiatives to prioritize commercial execution.
- Dyadic is transitioning from a platform technology company to a product commercialization model, with multiple products now entering commercial channels and generating early revenue.
- +7 more takeaways
Worksport Limited Q1 2026 Earnings Call - Revenue Surges 48% as SOLIS and COR Launches Fuel a Pivot to Profitability
Worksport Limited delivered a quarter defined by aggressive product expansion and strategic reinvestment rather than immediate profitability. Revenue climbed 48% year-over-year to $3.3 million, driven...
- Revenue grew approximately 48% year-over-year to $3.3 million in Q1 2026, with gross profit more than doubling to $854,000.
- Gross margins improved significantly to 26% in Q1 2026, up from 18% in the prior year, reflecting a strategic shift toward higher-margin B2B channels and domestic manufacturing efficiencies.
- The company launched two new major product lines: the SOLIS solar tonneau cover and the COR modular portable energy system, both of which received necessary UL and CSA certifications for North American distribution.
- +7 more takeaways
Amdocs Q2 2026 Earnings Call - New CEO Pins Hopes on 'Agentic' Telco Transformation
Amdocs reported solid Q2 2026 results, beating guidance on both revenue and earnings, but the real story is the leadership transition and strategic pivot. CEO Shimie Hortig, in his first full earnings...
- Q2 2026 revenue hit $1.17 billion, beating the midpoint of guidance, with non-GAAP diluted EPS of $1.78, also above expectations.
- CEO Shimie Hortig is repositioning Amdocs as the primary partner for telecom operators navigating the 'agentic era,' leveraging deep industry domain expertise and mission-critical system experience.
- Amdocs launched aOS (Agentic Operating System) for telcos, with early commercial deployments at PLDT, Cricket, Lumen, Bell Canada, and EchoStar.
- +9 more takeaways